Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,456 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,550 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03392233 | Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors | recruiting | Phase 2 | 100 | RenJi HospitalOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02182063 | A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer | completed | Phase 2 | 81 | Boehringer IngelheimINDUSTRY | 0 | Dec 28, 2017 | clinicaltrials |
| NCT03356912 |
| CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy |
| unknown |
| Phase 2 |
| 220 |
| Consorzio OncotechOTHER |
| 1 |
| Dec 14, 2017 |
| clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT00003533 | Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 12 | Burzynski Research InstituteOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00348816 | Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer | terminated | Phase 2 | 21 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00630344 | RAD001 and Bicalutamide for Androgen Independent Prostate Cancer | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT01200810 | Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00477087 | Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer | terminated | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT03356444 | Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate | unknown | Phase 2 | 140 | West China HospitalOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00307294 | Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) | completed | Phase 2 | 40 | University of PittsburghOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00466752 | Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer | completed | Phase 2 | 5 | University of WashingtonOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00524589 | Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT03344822 | Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients(TePSMAG-68) | unknown | Phase 2 / Phase 3 | 33 | Central Hospital, Nancy, FranceOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01240551 | F-18 Sodium Fluoride in Prostate Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00331344 | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | completed | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2017 | clinicaltrials |
| NCT02793219 | Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02793765 | Docetaxel Followed by Provenge in Metastatic Prostate Cancer | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT00060528 | Sequential Vaccinations in Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 26, 2017 | clinicaltrials |
| NCT00844792 | Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 48 | University Health Network, TorontoOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01992042 | Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer | completed | Phase 2 | 33 | University Health Network, TorontoOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01288534 | Hypofractionated Stereotactic Body Radiation Therapy (SBRT) | completed | Phase 2 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT01756638 | A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer | completed | Phase 2 | 48 | Janssen Research & Development, LLCINDUSTRY | 1 | Oct 23, 2017 | clinicaltrials |
| NCT00887458 | A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy | completed | Phase 2 | 46 | Johns Hopkins UniversityOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT02724618 | Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT) | unknown | Phase 2 | 64 | Shahid Beheshti University of Medical SciencesOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT00953225 | Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer(vit D & PCa) | completed | Phase 2 | 83 | VA Office of Research and DevelopmentFED | 1 | Oct 9, 2017 | clinicaltrials |
| NCT00480857 | Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy | terminated | Phase 2 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00589472 | Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer(TARGET) | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00195039 | Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer | completed | Phase 2 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 5, 2017 | clinicaltrials |
| NCT03297385 | Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation(DARANA) | completed | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 0 | Sep 29, 2017 | clinicaltrials |
| NCT01834651 | A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases | completed | Phase 2 | 17 | Edwin Posadas, MDOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02844699 | A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer | unknown | Phase 1 / Phase 2 | 24 | Panacela Labs LLCINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT01145508 | Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2017 | clinicaltrials |
| NCT00078585 | PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | completed | Phase 2 | 120 | Bavarian NordicINDUSTRY | 1 | Sep 11, 2017 | clinicaltrials |
| NCT00585962 | Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate | completed | Phase 2 | 57 | Massachusetts General HospitalOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT01866423 | Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 4 | University of Southern CaliforniaOTHER | 1 | Aug 31, 2017 | clinicaltrials |
| NCT00678054 | Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA) | completed | Phase 2 | 30 | University of California, San FranciscoOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02810886 | Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management(ProsPERo) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 0 | Aug 22, 2017 | clinicaltrials |
| NCT02452307 | Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy | unknown | Phase 1 / Phase 2 | 36 | University Hospital TuebingenOTHER | 0 | Aug 17, 2017 | clinicaltrials |
| NCT02391051 | Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial(FOKAL-BT) | recruiting | Phase 2 | 50 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Aug 11, 2017 | clinicaltrials |
| NCT00251225 | A Study of Imatinib and Docetaxel in Prostate Cancer | completed | Phase 2 | 49 | Leonard ApplemanOTHER | 1 | Aug 9, 2017 | clinicaltrials |
| NCT00551525 | Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 67 | Radiation Therapy Oncology GroupNETWORK | 1 | Jul 25, 2017 | clinicaltrials |
| NCT00851916 | CyberKnife Radiosurgery for Locally Recurrent Prostate CA | unknown | Phase 2 | 20 | CyberKnife Centers of San DiegoOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01045148 | CyberKnife Radiosurgery for Localized Prostatic Carcinoma | unknown | Phase 2 | 258 | CyberKnife Centers of San DiegoOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00005096 | Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT00003622 | Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy | withdrawn | Phase 2 | 0 | James AhlgrenOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00924313 | Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01240629 | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 43 | University of Southern CaliforniaOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01685125 | Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 2 | 96 | University of Southern CaliforniaOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT03211052 | A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone(NEPTUNE) | terminated | Phase 2 | 16 | Centre of Experimental MedicineOTHER | 1 | Jul 7, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Jan 5, 2018source: clinicaltrials